News

Weill Cornell Medicine has recently promoted longtime institutional leaders Thomas W. Stokes, Michael T. Murphy and Eric M. Saidel to elevated administrative posts.

Increasing the levels of chemicals naturally produced in the body called endocannabinoids may thwart the highly addictive nature of opioids such as morphine and oxycodone while maintaining the drugs’ ability to relieve pain, according to a new preclinical study by Weill Cornell Medicine investigators.

Severe COVID-19 arises in part from the SARS-CoV-2 virus’s impact on mitochondria, tiny oxygen-burning power plants in cells, which can help trigger a cascade of organ- and immune system-damaging events, suggests a study by investigators at Weill Cornell Medicine, Johns Hopkins Medicine, Children’s Hospital of Philadelphia, and the University of Pittsburgh School of Medicine, along with other members of the COVID-19 International Research Team.

Inhibiting an immune signaling protein called TLR7 may help preserve the protective layer surrounding nerve fibers in the brain during both Alzheimer’s disease and ordinary aging, suggests a study led by researchers at Weill Cornell Medicine.

A fungus discovered in the mouse stomach may hold a key to fungal evolution within the gastrointestinal tract, according to new research led by Weill Cornell Medicine investigators. 

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.

 Awards, honors and achievements for the month of November.

The secret to cellular youth may depend on keeping the nucleolus—a condensed structure inside the nucleus of a cell—small, according to Weill Cornell Medicine investigators. The findings were elucidated in yeast, a model organism famous for making bread and beer and yet surprisingly similar to humans on the cellular level.

Working with week-old zebrafish larva, researchers at Weill Cornell Medicine and colleagues decoded how the connections formed by a network of neurons in the brainstem guide the fishes’ gaze.

With just one slide and three minutes, fourth-year graduate student Erin Keblish described how she is developing a carbon nanotube-based sensor that could act like a “smoke detector” for early signs of deadly sepsis, during Weill Cornell Medicine’s ninth annual Three-Minute Thesis (3MT®) competition on November 13.

A novel combination of surgery and embolization used to treat subdural hematomas, bleeding between the brain and its protective membrane due to trauma, reduces the risk of follow-up surgeries, according to researchers at Weill Cornell Medicine and University at Buffalo.

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

The center connects health policy researchers across Cornell’s campuses to help shape effective health policy at the federal, state and local levels.

Hospices are increasingly owned by private equity firms and publicly traded companies, but recently Weill Cornell Medicine researchers found that they performed substantially worse than hospices owned by not-for-profit agencies. 

The awards recognized Dr. Harrington's career and leadership achievements.

Weill Cornell Medicine researchers have determined the full-length structure of a blood pressure-regulating hormone receptor for the first time, uncovering how it functions, which may enable better drug targeting of the receptor for diseases like hypertension and heart failure.

Weill Cornell Medicine has been awarded the Health Professions Higher Education Excellence in Diversity (HEED) Award by INSIGHT Into Diversity magazine, for the seventh consecutive year. 

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.

The award seeks to increase the number of early-stage investigators and enhance the diversity of the cancer research workforce to accelerate the fight against cancer.

Weill Cornell Medicine researchers have received a $6.2 million, five-year grant from the National Institute on Aging, part of the National Institutes of Health, to build a portable, high-resolution Positron Emission Tomography (PET) scanner that can detect the earliest stages of Alzheimer’s disease.